Clinical trials: Masked Hypertension
Glaucoma, Open-Angle
A Post-market Study Of Use Of The OMNI® Surgical System In Open Angle Glaucoma
To prospectively compare the clinical effect of the OMNI surgical system in eyes with Open Angle Glaucoma.
- Trial name
- NCT04616573
- Testing
- OMNI® Surgical System, iStent inject
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Sight Sciences, Inc.
Glaucoma and Ocular Hypertension
A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study
This is a Phase III, randomized, double-masked, active-controlled, parallel-group, multi-center study. Subjects diagnosed with glaucoma or OHT who meet eligibility criteria at Visit 1 (Screening) will washout of their current…
- Trial name
- NCT03691662
- Testing
- DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
- Where
- 34 sites in United States
- Volunteers
- 417 people
- Sponsor
- Santen Inc.
Glaucoma, Neovascular
Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients
To assess the efficacy and safety of the administration of aflibercept by intravitreal injection in comparison to sham to control intraocular pressure in patients with neovascular glaucoma.
- Trial name
- VEGA (NCT02396316)
- Testing
- Aflibercept (Eylea, BAY 86-5321)
- Where
- 19 sites in Japan
- Volunteers
- 54 people
- Sponsor
- Bayer
Ocular Hypertension, Open Angle Glaucoma
Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution
To evaluate effect of Netarsudil Ophthalmic Solution 0.02% on Nocturnal and Diurnal Intraocular Pressure.
- Trial name
- NCT02874846
- Testing
- Netarsudil ophthalmic solution 0.02%, Netarsudil Ophthalmic Solution Vehicle
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Aerie Pharmaceuticals
Primary Open-Angle Glaucoma, Ocular Hypertension
Dose-Ranging Study of the Bimatoprost Ocular Insert
The Bimatoprost Ocular Insert is intended to provide sustained delivery of bimatoprost to the ocular surface to lower the intraocular pressure (IOP) in patients with Open-Angle Glaucoma or Ocular Hypertension.
- Trial name
- NCT02358369
- Testing
- Bimatoprost, Timolol 0.5%
- Where
- 10 sites in United States
- Volunteers
- 156 people
- Sponsor
- ForSight Vision5, Inc.
Open-Angle Glaucoma, Ocular Hypertension
Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension
The purpose of this study is to evaluate the safety (in the eye and throughout the body) and effectiveness of nebivolol (0.5 and 1 percent) and timolol (0.5 percent) eye drop suspensions.
- Trial name
- NCT04910100
- Testing
- Nebivolol Ophthalmic Suspension 1 Percent, Nebivolol Ophthalmic Suspension 0.5 Percent, Timolol Ophthalmic Suspension 0.5 Percent
- Where
- United States
- Volunteers
- 226 people
- Sponsor
- Betaliq, Inc.
Open Angle Glaucoma, Ocular Hypertension
Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.
- Trial name
- Mont Blanc (NCT04445519)
- Testing
- NCX 470 0.065% (initial phase of trial), Latanoprost 0.005% (initial phase of trial), NCX 470 0.1% (initial phase of trial)
- Where
- United States
- Volunteers
- 691 people
- Sponsor
- Nicox Ophthalmics, Inc.
Primary Open Angle Glaucoma, Ocular Hypertension
Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Reduction of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop medications has been shown to be effective in delaying or preventing the progression of glaucoma, and it is the only proven method for…
- Trial name
- ANGEL-2 (NCT04742283)
- Testing
- DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID
- Where
- 41 sites in United States
- Volunteers
- 323 people
- Sponsor
- Santen Inc.
Open-Angle Glaucoma, Ocular Hypertension
Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension
In participants with a diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT), the primary objective is to demonstrate that the mean IOP reduction after 3 months of treatment with BOL-303259-X once daily (QD) is…
- Trial name
- LUNAR (NCT01749930)
- Testing
- BOL-303259-X, Timolol
- Where
- United States
- Volunteers
- 420 people
- Sponsor
- Bausch & Lomb Incorporated
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG
Phase II, randomized, double-masked study to evaluate the efficacy and tolerability of topical ocular delivery of fixed-dosed combinations of trabodenoson and latanoprost in subjects with Ocular Hypertension or Primary Open-Angle…
- Trial name
- NCT02829996
- Testing
- trabodenoson 6.0% / latanoprost 0.005% QD, trabodenoson 3.0% / latanoprost 0.005% QD, trabodenoson 6.0% / latanoprost 0.0025% QD
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Inotek Pharmaceuticals Corporation
Glaucoma, Open-Angle
A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure
This is a prospective, parallel-comparison, multi-center, double-masked, randomized, vehicle-controlled dose-response study assessing the safety and ocular hypotensive efficacy of VVN539 in subjects with POAG or OHT.
- Trial name
- NCT05451329
- Testing
- VVN539 Ophthalmic Solution 0.02%, VVN539 Ophthalmic Solution 0.04%, VVN539 Ophthalmic Solution Vehicle
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- VivaVision Biotech, Inc
Open Angle Glaucoma, Ocular Hypertension
Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure
To evaluate the ocular hypotensive efficacy of PG324 ophthalmic solution relative to its individual components in patients with open angle glaucoma or ocular hypertension.
- Trial name
- NCT02057575
- Testing
- PG324 Ophthalmic Solution 0.01%, PG324 Ophthalmic Solution 0.02%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%
- Where
- 23 sites in United States
- Volunteers
- 298 people
- Sponsor
- Aerie Pharmaceuticals
Angle-closure Glaucoma
Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)
The purpose of this study is to demonstrate that the Intraocular Pressure (IOP) lowering efficacy of Travoprost Ophthalmic Solution 0.004% is superior to that of Pilocarpine 1% in patients with chronic angle-closure glaucoma…
- Trial name
- NCT00762645
- Testing
- Travoprost 0.004% (Travatan), Pilocarpine 1%
- Volunteers
- 30 people
- Sponsor
- Alcon Research
Ocular Hypertension, Open-angle Glaucoma
Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
To evaluate the ocular hypotensive efficacy and ocular and systemic safety of AR-13324 Ophthalmic Solution, 0.02% compared to the active comparator Timolol maleate Ophthalmic Solution, 0.5%
- Trial name
- Rocket-1 (NCT02207491)
- Testing
- Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02%
- Where
- United States
- Volunteers
- 411 people
- Sponsor
- Aerie Pharmaceuticals
Open Angle Glaucoma, Ocular Hypertension
Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT
The objective of the study is to evaluate evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle…
- Trial name
- NCT02914509
- Testing
- Travoprost
- Where
- 10 sites in United States
- Volunteers
- 565 people
- Sponsor
- Ocular Therapeutix, Inc.
Open-Angle Glaucoma, Ocular Hypertension
A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to determine if a combination of two drugs (bimatoprost and timolol) delivered to the surface of the eye over 10 weeks is better at lowering intraocular pressure (IOP) than either of the drugs…
- Trial name
- NCT02742649
- Testing
- Fixed Combination, Bimatoprost, Timolol
- Where
- Panama
- Volunteers
- 55 people
- Sponsor
- ForSight Vision5, Inc.
Open-Angle Glaucoma, Ocular Hypertension
Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension
In participants with a diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT), the primary objective is to demonstrate that the mean IOP reduction after 3 months of treatment with BOL-303259-X once daily (QD) is…
- Trial name
- APOLLO (NCT01749904)
- Testing
- BOL-303259-X, Timolol
- Where
- United States
- Volunteers
- 420 people
- Sponsor
- Bausch & Lomb Incorporated
Primary Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
To evaluate the safety and efficacy of PF-04217329.
- Trial name
- NCT00572455
- Testing
- PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, PF-04217329 - Middle Dose
- Where
- 23 sites in United States
- Volunteers
- 318 people
- Sponsor
- Pfizer
Ocular Hypertension, Open Angle Glaucoma
Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure
Double-masked, randomized, multi-center, dose-response, active-controlled parallel-comparison of AR-13324 to latanoprost
- Trial name
- NCT01731002
- Testing
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, Latanoprost ophthalmic solution 0.005%
- Where
- 22 sites in United States
- Volunteers
- 224 people
- Sponsor
- Aerie Pharmaceuticals
Open-angle Glaucoma, Ocular Hypertension
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
To evaluate ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution.
- Trial name
- NCT02558374
- Testing
- AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID
- Where
- United States
- Volunteers
- 708 people
- Sponsor
- Aerie Pharmaceuticals